Diakonos Oncology is a clinical-stage immuno-oncology company founded in 2016 and headquartered in Houston, Texas. The firm is dedicated to advancing novel cancer treatments, including its lead therapeutic candidate DOC1021.
Subscribe to see Diakonos Oncology’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Diakonos Oncology is an immunotherapy company headquartered in Houston, United States. Xcout tracks 12 named people at Diakonos Oncology, including Mike Wicks (CEO and Board Member).
As of 16 November 2026. Source: Xcout Intel.
6 more named people on record for Diakonos Oncology, with roles, board committees and tenure — see the full roster →
A few of Diakonos Oncology's closest competitors — see the full list of competitors and alternatives →
Arch Oncology is a clinical-stage immuno-oncology company headquartered in Brisbane, California, with an additional scientific research laboratory in St. Louis, Missouri. The company develops antibody-based cancer therapies.
ARMO BioSciences is a late-stage immuno-oncology company that develops a pipeline of novel, proprietary product candidates designed to activate the immune system of cancer patients to recognize and eradicate tumors.
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company headquartered in South San Francisco, California. It specializes in developing novel T-cell engaging therapies for the treatment of cancer.
Arkgen Bioscions is a South Korean immuno-oncology startup headquartered in Daejeon. The company recently raised a $6.67 million Series A funding round to advance its proprietary biotech research. It focuses on developing innovative biopharmaceutical treatments.
OncoMyx Therapeutics, Inc. is a biotechnology company headquartered in Phoenix, Arizona, that develops innovative oncolytic immunotherapies to target and destroy tumors.
Codiak BioSciences, Inc. was a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company focused on developing exosome-based therapeutics.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Diakonos Oncology? Suggest a correction · Work at Diakonos Oncology? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.